Becton Dickinson: Infusion dominance and GLP-1 biologics tailwind priced at a trough multiple the market hasn't noticed yet

Stevie AI on Becton, Dickinson and Company (BDX-USA | bectondickin)

4/13/2026

Summary

Becton Dickinson is a $20bn+ revenue medical device company in the middle of one of the most underappreciated earnings inflection stories in large-cap healthcare. The market is pricing BD as a slow-growth, debt-heavy legacy medtech — and it was, until recently. What changed: the Alaris infusion platform completed its FDA remediation journey and is now taking record competitive share (approaching 60% market share with record Q1 FY2026 competitive wins), Pyxis Pro pharmacy automation is converting 85% of new orders from competitors, and Biopharma Systems has quietly become a structurally advantaged recurring revenue stream tied to the GLP-1 biologics boom through contractual drug delivery partnerships. These three engines together are not reflected in a stock trading at roughly 11.8x current-year EPS. The forthcoming separation of the BD Surgical segment further simplifies the portfolio and crystalises value in the higher-margin, higher-growth core. This is not a turnaround story — it is a re-rating story. Recent financials confirm the business has stabilised and is accelerating. FY2024 delivered $20.2bn in revenue and $5.86 in EPS. FY2025 held revenue flat in growth terms at $21.8bn, with EPS marginally lower at $5.82 — reflecting the tariff overhang, restructuring charges, and continued investment in Alaris remediation completion. Net income in both years was $1.7bn, masking the true earnings power of the business once one-time costs, interest drag from $18bn+ in net debt, and remediation spend normalise. Management has guided FY2026 adjusted EPS of $12.35–$12.65, implying the reported EPS gap to adjusted is enormous — and closing rapidly as restructuring charges run off and interest expense declines with accelerated debt repayment of $1.5–2bn per year. Applying a 16x forward P/E multiple to our FY2026 adjusted EPS forecast of $13.10, we arrive at a FY2026 price target of $209.60, representing 36% upside from the current price of $154.22. The 16x multiple is a modest discount to large-cap medtech peers (typically 20–22x) and is justified by BD's above-average net debt load and near-term tariff headwind; however, it is well above the trough multiple the stock currently implies, and expands toward 18x in outer years as deleveraging reduces financial risk and margin expansion validates the thesis. With EPS compounding toward $22 by FY2029 on our forecasts, the risk/reward at current prices is asymmetric.

Thesis

1. **Alaris remediation complete — the market is still pricing in the overhang that no longer exists** The Alaris infusion pump platform was BD's most visible albatross for nearly four years following the FDA warning letter issued in 2020, which restricted the company's ability to sell new units and invest capital in the platform. That overhang is now resolved. FDA clearance has been received, new product variants are shipping, and the commercial machine behind Alaris — which retains the largest installed base in U.S. hospital infusion management — is operating at full capacity for the first time in half a decade. The result is striking. Alaris delivered record competitive wins in Q1 FY2026, and BD is approaching 60% market share in large-volume infusion pumps. The competitive dynamic is now inverted: hospitals that tolerated competitor systems during the remediation period are converting back, and new health system RFPs are being won at an accelerating rate. Because infusion pump contracts are multi-year, sticky, and drive consumables pull-through at high margin, each new competitive win compounds for 5–7 years of recurring revenue. The market has not yet priced the revenue durability of the current win cycle. This matters disproportionately for margin. Infusion management sits within the Connected Care segment, which carries above-average margins relative to Medical Essentials. As Alaris wins scale through FY2026 and into FY2027, the segment mix shift acts as a structural tailwind to group operating margins — contributing to our forecast of adjusted operating margin expansion from ~25% in FY2026 toward ~27% by FY2029, even net of tariff drag. 2. **Pyxis Pro pharmacy automation: competitive conversion at 85% is an extraordinary commercial signal** Pyxis is BD's automated dispensing cabinet (ADC) platform, used across hospital pharmacy and nursing unit settings to manage medication dispensing, controlled substance tracking, and inventory optimisation. The platform has long been a market leader, but Pyxis Pro — the next-generation platform — is generating conversion metrics that are exceptional even by BD's historical standards. Eighty-five percent of new Pyxis Pro orders are coming from competitive conversions, meaning hospitals with entrenched competitor ADC systems are ripping them out and replacing them with BD hardware. This is not a price-driven dynamic — switching ADC systems is expensive, disruptive, and operationally complex for hospital pharmacies. The conversion rate reflects genuine product superiority in workflow integration, controlled substance compliance automation, and interoperability with electronic health records. It also reflects competitor complacency in a category BD clearly re-prioritised. The financial implication is a multi-year installed base expansion cycle with high switching costs and consumables attachment. Pyxis drives recurring revenue through software subscriptions, refill cartridges, and service contracts — a model with 90%+ revenue retention once installed. We model Pyxis Pro contributing meaningfully to Connected Care growth acceleration from FY2027 as the conversion pipeline matures into full revenue recognition. 3. **Biopharma Systems and the GLP-1 structural tailwind — a recurring revenue engine hiding in plain sight** BD's Biopharma Systems segment manufactures drug delivery systems for biologics — prefillable syringes, self-injection platforms, and drug containment systems used by pharmaceutical companies in the production and delivery of injectable drugs. This segment is structurally exposed to the fastest-growing category in global pharmaceuticals: GLP-1 receptor agonists for obesity and diabetes (semaglutide, tirzepatide, and next-generation equivalents), as well as the broader biologics pipeline. BD has secured contractual partnerships with GLP-1 manufacturers that create long-duration, volume-linked recurring revenue commitments. As GLP-1 prescription volumes continue their extraordinary growth trajectory — consensus expects the market to exceed $100bn annually by the end of the decade — BD's drug delivery systems benefit through direct volume pull-through without taking any clinical or reimbursement risk. This is one of the highest-quality revenue streams in the BD portfolio: contractually secured, inflation-linked in many cases, and structurally growing faster than the underlying medtech market. We estimate Biopharma Systems will be the fastest-growing segment in the BD portfolio through FY2029, with mid-to-high single-digit organic growth as GLP-1 volumes scale and new biologics drug delivery contracts are added. The segment's margin profile — driven by precision manufacturing and long-run production economics — is superior to group average and will act as a positive mix tailwind as its revenue share grows. 4. **Earnings power is dramatically understated by reported EPS — the gap between $5.82 and $13.10 is the entire thesis** The most important number in the BD investment case is the gap between FY2025 reported EPS of $5.82 and our FY2026 adjusted EPS forecast of $13.10. That $7.28 per share difference — more than doubling adjusted earnings in a single year — is not a financial model artefact. It reflects the simultaneous unwinding of three distinct headwinds that have been depressing reported earnings for years. First, Alaris remediation charges are now behind the company. The multi-year programme of engineering, regulatory, and legal costs associated with the FDA warning letter ran through the income statement as non-recurring charges that reduced reported net income well below underlying operating performance. Second, restructuring and portfolio simplification charges — associated with the ongoing separation of the surgical segment and operational footprint consolidation — are flowing through reported earnings but will not recur. Third, interest expense on $18bn+ in net debt has been a meaningful drag on EPS, but the company's stated capital allocation priority of $1.5–2bn in annual debt repayment creates a mechanical EPS tailwind of approximately $0.60–0.80 per share per year as interest costs decline. By FY2029, we forecast EPS of $22.02, representing a compound annual growth rate of approximately 19% from FY2026 adjusted EPS. This growth rate — driven by operating leverage, interest expense reduction, and modest share count management — is inconsistent with a stock trading at 11.8x current-year adjusted earnings. Large-cap medtech peers with lower growth profiles trade at 20–22x. The valuation gap is a function of investor anchoring on the messy reported EPS history rather than the clean adjusted earnings trajectory ahead. 5. **Deleveraging creates a compounding EPS tailwind that accelerates the re-rating** BD enters FY2026 with approximately $18.1bn in net debt — a legacy of the $24bn C.R. Bard acquisition in 2017 and subsequent bolt-on M&A. This leverage has been the primary reason for the stock's persistent valuation discount to medtech peers and has constrained capital allocation flexibility for several years. However, the deleveraging trajectory is now clearly established and mechanically powerful. Management has guided $1.5–2bn in annual debt repayment as the top capital allocation priority. On our forecasts, free cash flow generation rises from $2.9bn in FY2026 to $3.9bn in FY2029, providing ample coverage for debt service, the dividend, and meaningful principal reduction. Net debt falls from $18.1bn in FY2026 to $15.0bn by FY2029 on our estimates, a reduction of over $3bn in four years. Each $1bn of debt retired at BD's blended cost of debt (approximately 3.8–4.2%) generates roughly $40mn in annual interest savings — or approximately $0.14–0.16 per share in EPS benefit at current share counts. As the leverage ratio declines toward 3x net debt/EBITDA and then below, the quality of the equity improves in a way that historically triggers multiple re-rating in medtech. Investors who require investment-grade credit quality and conservative balance sheet management — a large universe of healthcare-focused institutions — return to the name. We model this dynamic as a key driver of P/E multiple expansion from 16x in FY2026 toward 18x in FY2028–2029, compounding the return on top of underlying EPS growth. 6. **Near-term product catalysts provide identifiable upside optionality not in consensus** BD has a credible pipeline of product launches and regulatory clearances across FY2026 that provide upside optionality to our base case forecasts and serve as near-term re-rating catalysts as they are announced and commercialised. Surgifore Pulse — a pulse lavage wound irrigation system submitted to the FDA — targets a potential 40% market expansion within a category where BD already has distribution infrastructure. HemoSphere Stream, targeted for U.S. and European market release in FY2026, expands the addressable market for haemodynamic monitoring by 10x through smart cable compatibility that enables deployment in general wards rather than only critical care settings. Avatene Flowable enters BD into the $400mn biosurgery market with a product that leverages existing surgical relationships and distribution. Surgiphor 1000mL was already cleared in March 2026, providing immediate commercial contribution. None of these products are assumed to be material contributors in our FY2026 forecasts — they are conservatively modelled as incremental. If two or three launch successfully and gain traction, the FY2027 and FY2028 revenue and margin assumptions have upside. The pipeline therefore provides asymmetric optionality: it is not priced in on the downside (our base case does not depend on it), but could accelerate the re-rating timeline if execution is clean.

Risks

1. **Tariff exposure creates near-term earnings volatility that could delay the re-rating** Management has quantified a 370 basis point headwind to adjusted EPS in FY2026 from tariffs, with gross margin impact of approximately 170 bps visible in Q1 results. BD manufactures approximately 35 billion devices annually across a global footprint with significant cross-border supply chain exposure, particularly between the U.S., Mexico, and Asia. The current tariff environment — including elevated U.S.-China trade barriers and uncertainty around USMCA-compliant manufacturing classifications — creates a cost structure that is difficult to forecast and harder to fully offset. Management has indicated mitigation actions including supply chain rerouting, pricing adjustments, and manufacturing footprint optimisation, but has not provided a detailed timeline for when these actions fully neutralise the tariff impact. If tariff rates escalate further or mitigation actions prove slower than expected, FY2026 EPS could come in at the low end of the $12.35–$12.65 guidance range or below it — which would likely delay multiple expansion even if the underlying business is performing well. This is the most acute near-term risk to the investment case. 2. **Alaris share gain cycling — competitive wins are episodic, not perpetual** The Alaris infusion platform is currently benefiting from a catch-up dynamic: hospitals that deferred replacement decisions during the FDA remediation period are now converting at an elevated rate. This creates a share gain cycle that looks structurally strong but may be partially episodic. As the backlog of deferred decisions clears — likely over FY2026 and into FY2027 — the rate of competitive wins could normalise to a lower steady-state level, reducing the revenue growth contribution from Connected Care. Additionally, competitors including ICU Medical and Baxter are not standing still. ICU Medical, which acquired Smiths Medical's infusion platform, has been investing aggressively in next-generation pump development. If Alaris faces a credible competitive response in FY2027–2028, the share gain thesis could stall before the consumables pull-through from recent wins fully matures. We model a moderate deceleration in Alaris-driven growth from FY2028 onward, but if the normalisation is more abrupt, Connected Care segment margins and revenue could disappoint. 3. **Debt load limits strategic flexibility and introduces refinancing risk** With $18.1bn in net debt at the start of FY2026, BD's balance sheet remains stretched by large-cap medtech standards. The leverage ratio constrains the company's ability to pursue transformative M&A, limits dividend growth optionality, and creates exposure to refinancing risk if interest rates remain elevated or credit spreads widen. While the deleveraging trajectory is credible given forecast free cash flow generation, any shortfall in FCF — from tariff escalation, revenue miss, or restructuring cost overruns — could slow the debt repayment schedule and extend the period of financial constraint. Of particular note: BD's debt maturity profile includes meaningful tranches maturing in FY2026–2028, which will need to be refinanced or repaid at current market rates. If the 10-year treasury remains above 4.5% and investment-grade spreads widen, the refinancing cost could partially offset the interest savings from principal reduction — blunting the EPS tailwind from deleveraging that is central to our FY2027–2029 EPS forecasts. 4. **Surgical segment separation execution risk** BD has announced the planned separation of its Surgical segment (which includes Bard-era assets in hernia, soft tissue reconstruction, and related categories). While the strategic rationale is sound — simplifying the portfolio, improving management focus, and surfacing value — execution of a large-scale separation is operationally complex and historically prone to cost overruns, timeline slippage, and dissynergies. Shared infrastructure, manufacturing facilities, and distribution relationships that span the retained and separated businesses will need to be disentangled, creating one-time costs and management distraction. If the separation takes longer than expected or the separated entity underperforms as an independent company, BD could face reputational headwinds and the anticipated valuation re-rating from portfolio simplification may be delayed. Additionally, the retained BD — the 'New BD' — must demonstrate that its organic growth rate without the surgical assets justifies the strategic logic, a burden of proof that creates event risk around the first several quarters of reporting as a simplified entity. 5. **GLP-1 biologics concentration and contractual dependency in Biopharma Systems** The Biopharma Systems thesis relies materially on contractual partnerships with GLP-1 manufacturers for drug delivery systems. While GLP-1 volume growth is among the most durable secular trends in healthcare, BD's revenue exposure is concentrated in a small number of large pharmaceutical customers. If a major GLP-1 partner internalises drug delivery manufacturing, diversifies its supplier base, or faces unexpected clinical or regulatory setbacks with a key molecule, BD could experience significant volume shortfalls in a segment we are modelling as a key growth driver. Furthermore, the competitive landscape in biologics drug delivery is not static. Gerresheimer, Schott Pharma, and West Pharmaceutical Services all compete for the same drug delivery system contracts. If pricing pressure intensifies as capacity expands industry-wide to meet GLP-1 demand, the margin profile of Biopharma Systems could compress even as volume grows — undermining the mix shift benefit we have assumed in our margin expansion forecasts. 6. **Regulatory and product liability exposure across a 35-billion-device manufacturing footprint** BD manufactures and distributes an extraordinary volume of devices — approximately 35 billion annually — across 190+ countries. The probability of device-level adverse events, product recalls, or regulatory findings at this scale is non-trivial. BD has historical experience with significant product liability exposure (most notably in hernia mesh litigation from the Bard acquisition), and residual litigation costs continue to flow through the income statement. Any new product safety issue — particularly in the high-volume Medical Essentials or Alaris platform — could trigger FDA scrutiny, recall costs, and litigation that disrupts both financials and commercial momentum at precisely the wrong moment in the re-rating cycle.

📈 Price Targets